Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A recently published report has shown that Peregrine Pharmaceuticals' NHS76/PEP2 enhances the efficacy of multiple chemotherapeutic agents, including Bristol-Myers Squibb's Taxol, by up to threefold.
Subscribe to our email newsletter
Peregrine Pharmaceuticals today announced that a paper titled “NHS76/PEP2, a Fully Human Vasopermeability-Enhancing Agent to Increase the Uptake and Efficacy of Cancer Chemotherapy,”
The paper, which was published in the Clinical Cancer Research journal, shows that NHS76/PEP2 greatly enhanced the uptake and efficacy of a variety of chemotherapeutic agents in solid tumor models.
The publication contains data showing that pretreatment with NHS76/PEP2, Peregrine’s lead vasopermeability-enhancing agent (VEA), enhanced the efficacy of chemotherapy in tumors known to be sensitive to the specific drugs. In addition, the report shows that NHS76/PEP2 plus chemotherapy also generated responses in tumors normally resistant to specific therapies, such as MAD109 murine lung carcinoma treated with paclitaxel (Taxol), vinblastine (Eli Lilly’s Velban) or 5-FU.
Moreover, improvements in drug uptake were seen in as little as one to two hours following pretreatment with NHS76/PEP2.
NHS76/PEP2 is the result of a fusion protein between NHS76, a fully human version of one of Peregrine’s tumor necrosis therapy antibodies, and PEP2, a peptide derived from interleukin 2.